The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a controlled clinical trial.

The researchers determined the effect of diabetes on B-type natriuretic peptide (BNP) concentrations in patients presenting to the emergency department with dyspnea.

Who Took Part

The abstract describes 1,586 patients taking part.

PubMed tags the participants as both men and women.

The Breathing Not Properly Multinational Study was a prospective evaluation of 1,586 patients.

A subset of 922 patients was obtained and subdivided into the following groups: group 1 (n = 324), neither diabetes nor heart failure; group 2 (n = 107), diabetes and no heart failure; group 3 (n = 247), no diabetes and heart failure; group 4 (n = 183), both diabetes and heart failure; group 5 (n = 41), heart failure history with no diabetes; and group 6 (n = 20), heart failure history with diabetes.

How the Study Was Run

Patients from groups 1, 3, and 5 were matched to groups 2, 4, and 6, respectively, to have the same mean age, sex distribution, BMI, renal function, and New York Heart Association (NYHA) classification (for heart failure).

What Was Measured

PubMed files the paper under topics including Acute Disease, Age Factors, Area Under Curve, Biomarkers, Confidence Intervals, Diabetes Mellitus, Type 2 and Dyspnea.

What This Means in Plain Language

This is a controlled clinical trial of BNP (Nesiritide) in 1,586 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Diabetes care), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.